KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Inventory (2018 - 2025)

BioNTech SE's Inventory history spans 8 years, with the latest figure at $128.9 million for Q4 2025.

  • On a quarterly basis, Inventory fell 57.43% to $128.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $128.9 million, a 57.43% decrease, with the full-year FY2025 number at $125.1 million, down 58.69% from a year prior.
  • Inventory hit $128.9 million in Q4 2025 for BioNTech SE, down from $263.9 million in the prior quarter.
  • Over the last five years, Inventory for BNTX hit a ceiling of $12.5 billion in Q3 2021 and a floor of $20.9 million in Q1 2021.
  • Historically, Inventory has averaged $1.9 billion across 5 years, with a median of $380.0 million in 2023.
  • The widest YoY moves for Inventory: up 2370.25% in 2022, down 97.62% in 2022.
  • Tracing BNTX's Inventory over 5 years: stood at $574.8 million in 2021, then fell by 21.98% to $448.5 million in 2022, then dropped by 14.19% to $384.9 million in 2023, then fell by 21.34% to $302.7 million in 2024, then plummeted by 57.43% to $128.9 million in 2025.
  • Business Quant data shows Inventory for BNTX at $128.9 million in Q4 2025, $263.9 million in Q3 2025, and $261.1 million in Q2 2025.